Bristol-Myers Squibb BMY CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by Bristol-Myers Squibb in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The official record: Bristol-Myers Squibb’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bristol-Myers Squibb's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Bristol-Myers Squibb's capex?
- Bristol-Myers Squibb (BMY) reported capex of $347M in Q1 2026.
- How has Bristol-Myers Squibb's capex changed year-over-year?
- Bristol-Myers Squibb's capex increased by 33.5% year-over-year, from $260M to $347M.
- What is the long-term trend for Bristol-Myers Squibb's capex?
- Over 4 years (2021 to 2025), Bristol-Myers Squibb's capex has grown at a 7.7% compound annual growth rate (CAGR), from $973M to $1.31B.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.